BASF to adjust production at Minden site

Published: 14-Oct-2005

A significant decline in demand for pseudoephedrine and caffeine by the pharmaceutical sector has led to an 'adjustment' in production at BASF Pharma Chemikalien's site in Minden, Germany.


A significant decline in demand for pseudoephedrine and caffeine by the pharmaceutical sector has led to an 'adjustment' in production at BASF Pharma Chemikalien's site in Minden, Germany.

The change will result in a reduction in the workforce, with 95 jobs being lost through voluntary redundancy.

The reason for the decline in demand for pseudoephedrine is a change in the US, the world's largest market for the product. In future, pharmaceuticals that contain pseudoephedrine will no longer be sold over the counter, but will be available only on prescription. The main reason for the declining sales in caffeine is pricing pressure from manufacturers of the product in Asia.

The site currently has approximately 630 employees and its main sales products are caffeine and pseudoephedrine. 'The production adjustments are necessary to improve the international competitiveness of the Minden site," said Dr Roland Minges, managing director of BASF Pharma Chemikalien.

  

You may also like